Guinea-Bissau vs New Caledonia: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Guinea-Bissau
2.7%
in 2024
New Caledonia
2.3%
in 2024
Guinea-Bissau rank
9th
New Caledonia rank
12th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Guinea-Bissau
- New Caledonia
How they compare
Guinea-Bissau currently reports 2.7% against 2.3% in New Caledonia, a difference of 0.4%.
That makes Guinea-Bissau's figure about 1.2 times New Caledonia's.
Across all 10 years both countries report, Guinea-Bissau has been ahead every year.
Guinea-Bissau ranks 9th and New Caledonia ranks 12th of 246 countries.
Guinea-Bissau has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Guinea-Bissau | New Caledonia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2.8% | 1.9% | 0.9% | Guinea-Bissau |
| 2020s | 2.7% | 2.2% | 0.5% | Guinea-Bissau |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Guinea-Bissau or New Caledonia?
- Guinea-Bissau, at 2.7% against 2.3% in New Caledonia as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Guinea-Bissau and New Caledonia?
- 0.4%, with Guinea-Bissau ahead.
- How many years of comparable data are there for Guinea-Bissau and New Caledonia?
- 10 years are reported by both, from 2015 to 2024.
- How do Guinea-Bissau and New Caledonia rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Guinea-Bissau ranks 9th and New Caledonia ranks 12th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.